Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac
| dc.contributor.author | Laffi, G. | en |
| dc.contributor.author | Daskalopoulos, G. | en |
| dc.contributor.author | Kronborg, I. | en |
| dc.contributor.author | Hsueh, W. | en |
| dc.contributor.author | Gentilini, P. | en |
| dc.contributor.author | Zipser, R. D. | en |
| dc.date.accessioned | 2015-11-24T19:20:31Z | |
| dc.date.available | 2015-11-24T19:20:31Z | |
| dc.identifier.issn | 0016-5085 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22046 | |
| dc.rights | Default Licence | - |
| dc.subject | 6-Ketoprostaglandin F1 alpha/urine | en |
| dc.subject | Adult | en |
| dc.subject | Cyclooxygenase Inhibitors | en |
| dc.subject | Dinoprostone | en |
| dc.subject | Humans | en |
| dc.subject | Ibuprofen/*therapeutic use/toxicity | en |
| dc.subject | Indenes/*therapeutic use | en |
| dc.subject | Kidney/*drug effects/metabolism | en |
| dc.subject | Kidney Function Tests | en |
| dc.subject | Liver Cirrhosis, Alcoholic/*drug therapy | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prostaglandins E/urine | en |
| dc.subject | Renal Circulation/drug effects | en |
| dc.subject | Sulindac/*therapeutic use/toxicity | en |
| dc.subject | Thromboxane B2/metabolism | en |
| dc.subject | Time Factors | en |
| dc.title | Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac | en |
| heal.abstract | Nonsteroidal antiinflammatory drugs impair renal function in susceptible patients with cirrhosis and ascites. A new antiinflammatory drug, sulindac, is reported not to affect renal function. To evaluate its renal-sparing mechanism, sulindac was administered for 5 days and ibuprofen for 1 day to 10 patients and paraaminohippurate and inulin clearances, serum and urine eicosanoids, and serum and urine sulindac metabolites were monitored. Ibuprofen reduced renal clearances in the 5 subjects with greatest sodium retention, whereas sulindac had no effect. Plasma concentration of the active sulfide metabolite was markedly increased in liver patients, and this concentration correlated with the inhibition of serum thromboxane (r = 0.75, p = 0.01). The percent inhibition of serum thromboxane with sulindac administration correlated with the inhibition of urinary eicosanoids (r = 0.68-0.81, all p less than 0.02). Ibuprofen was generally a more potent inhibitor of serum and urine eicosanoids. Thus, a major factor in the renal-sparing effect of sulindac appears to be its less potent inhibition of renal and extrarenal cyclooxygenase systems. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/3079594 | - |
| heal.journalName | Gastroenterology | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 1986 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: